Q4 2024 Earnings Call Transcript May 29, 2025 Roivant Sciences Ltd. misses on earnings expectations. Reported EPS is $-0.22 ...

The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of ...

Discover key insights from Roivant Sciences' Q4 2024 earnings call. Learn about their robust pipeline, pivotal 2025 milestones, and capital strength.

Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Early diagnosis and treatment of generalized myasthenia gravis (MG) are important to achieve symptomatic control and limit relapses, but evidence suggests social resources may be not applied to this ...

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the ...

Generalized myasthenia gravis (gMG) is a chronic autoimmune disorder driven by the classical pathway that causes progressive muscle weakness. Over 100,000 people in the US are living with gMG and ...

at the influential 15 th Annual Myasthenia Gravis Foundation of America (MGFA) International Conference on Myasthenia and Related Disorders, taking place from 13-15 May in The Hague, Netherlands.